Sodium Acid Pyrophosphate
CAS 7758-16-9
Sodium Acid Pyrophosphate (CAS 7758-16-9) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| DISODIUM PYROPHOSPHATE | 267798 | SU | MTHSPL |
| SODIUM ACID PYROPHOSPHATE | 267798 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Acid Pyrophosphate used for in pharmaceutical contexts?
Sodium Acid Pyrophosphate (CAS 7758-16-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Acid Pyrophosphate?
No adverse-event association or SIDER side-effect rows are rendered for Sodium Acid Pyrophosphate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Acid Pyrophosphate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Disodium Pyrophosphate with EU status "permitted".
What clinical phase is Sodium Acid Pyrophosphate in?
Sodium Acid Pyrophosphate is rendered with ChEMBL max phase 2.